USPTO Art Unit 1693 Prosecution Statistics

Art Unit Information

Art Unit: 1693
Group: 1690
Tech Center: 1600
Total Cases: 1,621
Last Active: October 2025

Recent Applications

Detailed information about the 100 most recent patent applications.

Application NumberTitleFiling DateDisposal DateDispositionTime (months)Office ActionsRestrictionsInterviewAppeal
19371517HYDROXYPROPYL BETA-CYCLODEXTRIN COMPOSITIONS AND METHODSOctober 2025March 2026Allow400YesNo
19371529HYDROXYPROPYL BETA-CYCLODEXTRIN COMPOSITIONS AND METHODSOctober 2025March 2026Allow500YesNo
19350944HYDROXYPROPYL BETA-CYCLODEXTRIN COMPOSITIONS AND METHODSOctober 2025December 2025Allow300YesNo
19350939HYDROXYPROPYL BETA-CYCLODEXTRIN COMPOSITIONS AND METHODSOctober 2025February 2026Allow500YesNo
19350933HYDROXYPROPYL BETA-CYCLODEXTRIN COMPOSITIONS AND METHODSOctober 2025February 2026Allow500YesNo
19350713ADVANTAGEOUS MORPHIC FORM OF AT-527 HEMI-SULFATE SALTOctober 2025March 2026Abandon510NoNo
19317897METHOD FOR EXTRACTING UNFRACTIONATED HEPARIN FROM CAMEL INTESTINAL MUCOSASeptember 2025January 2026Allow510NoNo
19312906HYDROXYPROPYL BETA-CYCLODEXTRIN COMPOSITIONS AND METHODSAugust 2025February 2026Allow600YesNo
19278422HYDROXYPROPYL BETA-CYCLODEXTRIN COMPOSITIONS AND METHODSJuly 2025February 2026Allow700YesNo
19278380HYDROXYPROPYL BETA-CYCLODEXTRIN COMPOSITIONS AND METHODSJuly 2025February 2026Allow700YesNo
19278356HYDROXYPROPYL BETA-CYCLODEXTRIN COMPOSITIONS AND METHODSJuly 2025January 2026Allow600YesNo
19261756VIRAL INHIBITORS, THE SYNTHESIS THEREOF, AND INTERMEDIATES THERETOJuly 2025October 2025Allow410NoNo
19219596HYDROXYPROPYL BETA-CYCLODEXTRIN COMPOSITIONS AND METHODSMay 2025July 2025Allow200YesNo
19186434PHARMACEUTICAL COMPOSITIONS FOR TREATING OSTEOARTHRITISApril 2025October 2025Allow510YesNo
19184071METHOD FOR SEPARATING AND PURIFYING FUCOIDANApril 2025October 2025Allow510NoNo
19183918MODIFIED CELLULOSE AND THE PREPARATION METHOD AND APPLICATION THEREOFApril 2025September 2025Allow510NoNo
19175757HYDROXYPROPYL BETA-CYCLODEXTRIN COMPOSITIONS AND METHODSApril 2025June 2025Allow300YesNo
19067838QUATERNIZED CELLULOSE-BASED RESIN AND PREPARATION METHOD AND APPLICATION THEREOFMarch 2025September 2025Allow610NoNo
19066352RIBOSE-MODIFIED CAP ANALOG AND USE THEREOFFebruary 2025December 2025Allow1020NoNo
19061509HYDROXYPROPYL BETA-CYCLODEXTRIN COMPOSITIONS AND METHODSFebruary 2025May 2025Allow200YesNo
19061577HYDROXYPROPYL BETA-CYCLODEXTRIN COMPOSITIONS AND METHODSFebruary 2025May 2025Allow300YesNo
19045102MEDICAL USE OF TAFOXIPARINFebruary 2025July 2025Allow510YesNo
19031698NICOTINAMIDE RIBOSIDE HYDROGEN MALATE CRYSTAL, AND ITS PREPARATION METHOD AND APPLICATIONJanuary 2025April 2025Allow300NoNo
19028631HYDROXYPROPYL BETA-CYCLODEXTRIN COMPOSITIONS AND METHODSJanuary 2025May 2025Allow410YesNo
19002355POSITIVE MODULATORS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M4December 2024November 2025Abandon1110NoNo
19002083POSITIVE MODULATORS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M4December 2024October 2025Abandon1010NoNo
19002334POSITIVE MODULATORS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M4December 2024November 2025Abandon1110NoNo
19002103POSITIVE MODULATORS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M4December 2024June 2025Allow610NoNo
19002368POSITIVE MODULATORS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M4December 2024October 2025Allow1020YesNo
18990523PSEUDO NARCOTIC TRAINING DEVICEDecember 2024May 2025Allow501YesNo
18988105ACETYLATED RIBONUCLEIC ACIDS AND USES THEREOFDecember 2024July 2025Allow710NoNo
18978008USE OF OLEANOLIC ACID-28-O-BETA-D-GLUCOPYRANOSIDE IN PREPARATION OF ANTI-COLITIS DRUGDecember 2024September 2025Allow920YesNo
18963281METHOD OF MAKING NICOTINAMIDE RIBOFURANOSIDE SALTS, NICOTINAMIDE RIBOFURANOSIDE SALTS AS SUCH, AND USES THEREOFNovember 2024April 2025Allow510NoNo
18960884PHARMACEUTICAL COMPOSITIONS FOR TREATING OSTEOARTHRITISNovember 2024October 2025Allow1130YesNo
18957502IMMUNOPHILIN BINDING AGENTS AND USES THEREOFNovember 2024October 2025Allow1120NoNo
18930999COMPOSITION FOR MAKEUP REMOVAL AND METHODS FOR PREPARING, PACKAGING, AND USING SAME, AND MAKEUP REMOVING GELOctober 2024August 2025Allow911YesNo
18921816BACTERIAL DNA GYRASE INHIBITORS AND METHODS OF USE THEREOFOctober 2024January 2026Allow1531YesNo
18905854POLYMER BEADS FOR OLIGONUCLEOTIDE SYNTHESISOctober 2024June 2025Allow811YesNo
18889398METHODS AND KITS USEFUL FOR DIAGNOSIS OF HUMAN PAPILLOMAVIRUS (HPV)September 2024February 2025Allow420NoNo
18885065GLP-1R Agonist and Therapeutic Method ThereofSeptember 2024December 2024Allow300YesNo
18828652MARIBAVIR ISOMERS, COMPOSITIONS, METHODS OF MAKING AND METHODS OF USINGSeptember 2024April 2025Allow720NoNo
18814957COGNITIONAugust 2024September 2025Allow1320YesNo
18813024BETA-GLUCAN-RICH LENTINULA EDODES POLYSACCHARIDE AND PREPARATION METHOD THEREOFAugust 2024November 2024Allow200NoNo
18840839POLYMORPHIC FORM OF REDUCED BETA-NICOTINAMIDE MONONUCLEOTIDE DISODIUM SALT, AND PREPARATION METHOD THEREFOR AND USE THEREOFAugust 2024November 2025Allow1500YesNo
18792393ARNATAR COMPOUNDS AND METHODS FOR ENHANCED CELLULAR UPTAKEAugust 2024October 2024Allow300NoNo
18792077COLON-TARGETED ACTIVE AGENT DELIVERY CARRIER AND USES THEREOFAugust 2024June 2025Allow1030YesNo
18777489VIRAL INHIBITORS, THE SYNTHESIS THEREOF, AND INTERMEDIATES THERETOJuly 2024April 2025Allow820NoNo
18777473VIRAL INHIBITORS, THE SYNTHESIS THEREOF, AND INTERMEDIATES THERETOJuly 2024January 2025Allow610NoNo
18777501VIRAL INHIBITORS, THE SYNTHESIS THEREOF, AND INTERMEDIATES THERETOJuly 2024January 2025Allow610YesNo
18769736METHOD FOR OBTAINING SULFATED NANOPARTICLES OF CELLULOSE AND MANNAN FROM ENDOSPERMSJuly 2024March 2025Allow810YesNo
18765449PREBIOTIC COMPOSITIONS AND METHODS OF PRODUCTION THEREOFJuly 2024August 2025Abandon1310NoNo
18762939REGIMENS FOR TREATING HIV INFECTIONS AND AIDSJuly 2024October 2024Allow410YesNo
18750829POSITIVE MODULATORS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M4June 2024May 2025Allow1020YesNo
18749007PROCESSES FOR PREPARING PHOSPHORODIAMIDATE MORPHOLINO OLIGOMERS VIA FAST-FLOW SYNTHESISJune 2024November 2025Allow1711YesNo
18680557AEROSOL AND TOPICAL ADMINISTRATION OF A FORMULATION CONTAINING CYCLODEXTRIN, QUERCETIN AND ZINC, IN COMBINATION OR SEPARATELY, TO MITIGATE INFECTION BY ENVELOPED VIRUSESMay 2024June 2025Abandon1310NoNo
18676985Method for Prolonging Half-life of Theanine In VivoMay 2024September 2024Allow420NoNo
18672453TRANSITION METAL COMPLEX ASSISTED GREEN HYDROLYSIS FOR NANOCELLULOSE EXTRACTIONMay 2024November 2024Allow610NoNo
18672651Modified Nucleoside PhosphoramiditesMay 2024June 2025Allow1310NoNo
18711860COMPOSITIONS COMPRISING REACTION PRODUCTS OF SACCHARIDE POLYMERS AND FATTY ACIDS OR FATTY ESTERS FORMULATED WITH AN AMIDE-BASED NEUTRAL SURFACTANTMay 2024October 2025Allow1721NoNo
18667496C-TERMINAL HSP90 INHIBITORSMay 2024March 2026Allow2200YesNo
18654457USE OF CHONDROITIN SULFATE FOR RELIEVING OCULAR PAINMay 2024August 2025Allow1520YesNo
18652718INJECTABLE ANTIBIOTIC FORMULATIONS AND USE THEREOFMay 2024April 2025Allow1110NoNo
18651620METHODS FOR EXTRACTING XYLOSE LIQUID AND CELLULOSE WITH HIGH PURITY FROM CORN STRAWApril 2024January 2025Allow910NoNo
18646230FUNCTIONALIZED N-ACETYLGALACTOSAMINE ANALOGSApril 2024February 2026Allow2100YesNo
18646035USE OF MARIBAVIR IN TREATMENT REGIMENSApril 2024October 2024Allow610NoNo
18641536COMPOSITIONS AND METHODS FOR TREATMENT OF DIABETIC NEUROPATHIESApril 2024September 2025Allow1720YesNo
18639619TOPICAL COMPOSITIONSApril 2024August 2024Allow410YesNo
18639630TOPICAL COMPOSITIONSApril 2024September 2024Allow510YesNo
18633063COMPOSITIONS OF HYDROXYPROPYL-BETA-CYCLODEXTRIN AND METHODS OF PURIFYING THE SAMEApril 2024September 2024Allow510YesNo
18633087COMPOSITIONS OF HYDROXYPROPYL-BETA-CYCLODEXTRIN AND METHODS OF PURIFYING THE SAMEApril 2024November 2024Allow710YesNo
18630197CONJUGATES COMPRISING CLEAVABLE LINKERSApril 2024October 2024Allow610NoNo
18629820INHIBITORS OF ADENOSINE 5'-NUCLEOTIDASEApril 2024July 2024Allow300NoNo
18609604TREATMENT OF HEARING LOSSMarch 2024October 2024Allow700NoNo
18598995NUCLEOTIDE CLEAVABLE LINKERS AND USES THEREOFMarch 2024January 2026Allow2200YesNo
18597197MARIBAVIR ISOMERS, COMPOSITIONS, METHODS OF MAKING AND METHODS OF USINGMarch 2024April 2025Abandon1310NoNo
18594712MARIBAVIR ISOMERS, COMPOSITIONS, METHODS OF MAKING AND METHODS OF USINGMarch 2024April 2025Abandon1310NoNo
18593522METHOD FOR PRODUCING D-ALLULOSE CRYSTALSMarch 2024November 2025Allow2111YesNo
18687295PHARMACEUTICAL COMPOSITIONFebruary 2024March 2025Allow1220YesNo
18584219OPHTHALMIC SOLUTIONSFebruary 2024October 2025Abandon2030NoNo
18443653BODY MILKFebruary 2024October 2025Allow2041YesYes
18444468METHODS, AGENTS, AND DEVICES FOR LOCAL NEUROMODULATION OF AUTONOMIC NERVESFebruary 2024January 2026Allow2321YesNo
18442204AZITHROMYCIN AND ROXITHROMYCIN DERIVTIVES AS SENOLYTIC DRUGSFebruary 2024September 2024Allow700NoNo
18441882CARBOHYDRATE CONJUGATED RNA AGENTS AND PROCESS FOR THEIR PREPARATIONFebruary 2024October 2025Allow2010NoNo
18438664MATERIALS AND METHODS FOR PURIFYING DNA, RNA, AND POLYPEPTIDESFebruary 2024March 2025Abandon1320YesNo
18437424DIARYL TREHALOSE COMPOUNDS AND USES THEREOFFebruary 2024August 2024Allow600NoNo
18435848Process for Preparing ImetelstatFebruary 2024December 2024Allow1010NoNo
18433651COMPOSITIONS COMPRISING 2'-DEOXYCYTIDINE ANALOGS AND USE THEREOF FOR THE TREATMENT OF SICKLE CELL DISEASE, THALASSEMIA, AND CANCERSFebruary 2024July 2025Abandon1810NoNo
18430984METHODS FOR TREATMENT OR PREVENTION OF DAMAGE RESULTING FROM RADIATION, TRAUMA OR SHOCKFebruary 2024November 2025Allow2110YesNo
18431303SELECTIVE 3-PRENYL 5-METHYL ETHER, 7-O-RHAMNOSIDE FLAVONE FOR THE TREATMENT OF HEPATIC CANCERFebruary 2024September 2024Allow710NoNo
18430551FORMULATIONS AND METHODS FOR TREATING CONDITIONS OF THE EYEFebruary 2024December 2025Abandon2220NoNo
18429102ULTRASOUND-ASSISTED METHOD FOR HIGH-YIELD CELLULOSE EXTRACTION FROM RAW RICE STRAW WITHOUT THE NEED FOR BLEACHING STEPJanuary 2024September 2024Allow810NoNo
18424626PHARMACEUTICAL COMPOSITIONS FOR TREATING OSTEOARTHRITISJanuary 2024March 2025Allow1321YesNo
18422333PHARMACEUTICAL COMPOSITION, METHODS FOR TREATING AND USES THEREOFJanuary 2024September 2025Abandon1910NoNo
18420540METHODS OF SELECTIVELY MODULATING GASTROINTESTINAL MICROBIAL GROWTHJanuary 2024April 2025Allow1520YesNo
18417034Process For Purifying Sialylated OligosaccharidesJanuary 2024January 2026Allow2430NoNo
18417807COMPOSITIONS AND METHODS FOR MODULATING APOLIPOPROTEIN C-III EXPRESSIONJanuary 2024April 2025Allow1510NoNo
18417312LIQUID COMPOSITION COMPRISING GLUCOSEJanuary 2024August 2024Allow700YesNo
18411265TREATMENT OF SLEEP APNEA WITH A COMBINATION OF A CARBONIC ANHYDRASE INHIBITOR AND AN ALDOSTERONE ANTAGONISTJanuary 2024December 2025Abandon2311NoNo
18412414COMPOSITIONS AND METHODS FOR REDUCING MAJOR THROMBOTIC EVENTS IN CANCER PATIENTSJanuary 2024January 2025Allow1210NoNo
18410236COMPOUNDS AND METHODS FOR TREATMENT OF VIRAL INFECTIONSJanuary 2024January 2025Allow1310NoNo

Appeals Overview

This analysis examines appeal outcomes and the strategic value of filing appeals for art-unit 1693.

Patent Trial and Appeal Board (PTAB) Decisions

Total PTAB Decisions
32
Examiner Affirmed
16
(50.0%)
Examiner Reversed
16
(50.0%)
Reversal Percentile
93.8%
Higher than average

What This Means

With a 50.0% reversal rate, the PTAB reverses the examiner's rejections in a meaningful percentage of cases. This reversal rate is in the top 25% across the USPTO, indicating that appeals are more successful here than in most other areas.

Strategic Value of Filing an Appeal

Total Appeal Filings
170
Allowed After Appeal Filing
57
(33.5%)
Not Allowed After Appeal Filing
113
(66.5%)
Filing Benefit Percentile
56.5%
Higher than average

Understanding Appeal Filing Strategy

Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.

In this dataset, 33.5% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is above the USPTO average, suggesting that filing an appeal can be an effective strategy for prompting reconsideration.

Strategic Recommendations

✓ Appeals to PTAB show good success rates. If you have a strong case on the merits, consider fully prosecuting the appeal to a Board decision.

✓ Filing a Notice of Appeal is strategically valuable. The act of filing often prompts favorable reconsideration during the mandatory appeal conference.

Art Unit 1693 - Prosecution Statistics Summary

Executive Summary

Art Unit 1693 is part of Group 1690 in Technology Center 1600. This art unit has examined 1,621 patent applications in our dataset, with an overall allowance rate of 86.6%. Applications typically reach final disposition in approximately 41 months.

Comparative Analysis

Art Unit 1693's allowance rate of 86.6% places it in the 83% percentile among all USPTO art units. This art unit has a significantly higher allowance rate than most art units at the USPTO.

Prosecution Patterns

Applications in Art Unit 1693 receive an average of 2.24 office actions before reaching final disposition (in the 76% percentile). The median prosecution time is 41 months (in the 11% percentile).

Strategic Considerations

When prosecuting applications in this art unit, consider the following:

  • The art unit's allowance rate suggests a more favorable examination environment compared to the USPTO average.
  • With more office actions than average, plan for multiple rounds of prosecution.
  • The median prosecution time is longer than average and should be factored into your continuation and client communication strategies.
  • Review individual examiner statistics within this art unit to identify examiners with particularly favorable or challenging prosecution patterns.

Important Disclaimer

Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.

No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.

Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.

Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.